Continued positive momentum in Q3 led to healthy overall company performance
During the third quarter of 2015, Lonza’s business performance continued to show positive momentum.
The Pharma&Biotech segment contributed to the healthy overall performance.
Richard Ridinger, CEO of Lonza, said Lonza’s financial situation 'remains robust as we continue our path of stabilisation'.
He added that this 'demonstrates the benefits from our ongoing improvement projects that emphasise organic growth and quality matters as we continue to streamline our portfolio'.
The Pharma&Biotech (LPB) segment’s good performance was driven by commercial Mammalian Manufacturing and Emerging Technologies (antibody drug conjugates, viral therapy and cell therapy), with good capacity utilisation across all assets.
In Microbial Manufacturing and Small Molecules, Lonza continued activities to improve its product mix and optimise the portfolio.
The re-design of the microbial fermentation plant in Visp, Switzerland into a multi-purpose facility to accommodate additional demand and new customers is proceeding as planned and meets market interest in microbial biologics.
Lonza’s financial situation remains robust as we continue our path of stabilisation
Lonza’s Emerging Technologies business continued to grow and expand. Viral Therapy’s plans to expand commercial manufacturing in Houston, Texas, US are being well received by customers, the firm said. Cell Therapy signed several contracts for development of processes in bioreactors.
The Custom Development Services business experienced high demand for development services and clinical product supply and profited from investment flows into biotech companies. Lonza attracted a double-digit number of new customers for its development and clinical supply services.
Bioscience Solutions’ growth in Q3 over the previous year is expected to continue. This growth is a result of strong performance in both media biotherapeutics and MODA software, especially in North America, Europe and Asia Pacific.
So far in 2015, Lonza had 16 successful inspections of its pharma sites by regulatory authorities, as well as 109 audits by customers.
Based on constant exchange rates and taking into consideration the bi-yearly cracker shut-down in Visp in Q4, Lonza is confident that it will deliver sales growth in 2015.